A research team from the Technical University of Munich and the Max Planck Institute of Molecular Physiology has elucidated the structure of the proteolytic complex ClpX-ClpP. This is a key to development of innovative antibiotics which target the degradation process of defective proteins in bacteria. Courtesy of Dr. Christos Gatsogiannis/MPI of Molecular Physiology
Antibiotics are still the most important weapon for combatting bacterial infections. But medical science is running out of "ammunition" because of more and more frequently occurring resistances. Scientists from the Technical University of Munich and the Max Planck Institute of Molecular Physiology has now elucidated the structure of the proteolytic complex ClpX-ClpP. This is a key to development of innovative antibiotics which target the degradation process of defective proteins in bacteria.
Almost 700,000 people in Europe suffer from infections every year through antibiotic-resistant pathogens; approximately 33,000 of them die. Despite this enormous and globally increasing danger, very few new antibiotics have been developed and approved in the past few decades.
There is no improvement in sight. That is why it is urgently necessary to find new points of attack in pathogenic bacteria and to develop new antibiotics which exploit these weak spots.
A particularly promising point of attack for antibacterial therapies is the proteolytic enzyme ClpP: on the one hand it plays an important role in bacterial metabolism, and on the other hand it ensures the controlled degradation of defective proteins.
But for this purpose it requires the ClpX protein as a starting aid. In the complex with ClpP, ClpX identifies proteins which should be degraded, unfurls them and guides them into its barrel-like degradation chamber.
Scientists in the groups led by professor Stephan Sieber, Technical University of Munich (TUM) and professor Stefan Raunser, director at the Max Planck Institute of Molecular Physiology in Dortmund, have now elucidated the three-dimensional structure of the ClpX-ClpP proteolytic complex for the first time and thereby established an important basis for future pharmacological strategies.
A new class of potential antibiotics -- the so-called acyldepsipeptide (ADEP) antibiotics - also brings about an uncontrolled degradation through ClpP without the support of ClpX. As a result also vital proteins are destroyed -- with lethal consequences for the bacteria.
This unique mechanism of action has considerable innovation potential in the fight against pathogenic bacteria. Whereas common antibiotics act through the inhibition of vital processes, in this case the antibacterial effect is achieved through the activation of a process.
In addition to the degradation of defective proteins, ClpP is also a decisive regulator in the production of an arsenal of bacterial toxins which are primarily responsible for the pathogenic effect of many pathogens.
At the TUM, the group led by Prof. Stephan Sieber has been successfully researching the ClpP protease for years, and has already developed a large number of potent inhibitors against ClpP and ClpX which stop the production of bacterial toxins and can therefore more or less disarm them. Dóra Balogh has now managed to produce and stabilize the ClpX-ClpP complex.
But up to recently the structure of the ClpX-ClpP complex could not yet be elucidated in detail. Dr. Christos Gatsogiannis, researcher in the group led by professor Stefan Raunser at the MPI of Molecular Physiology, has now managed this by means of cryogenic electron microscopy.
With this technology they were able to demonstrate that ADEP and ClpX dock onto ClpP at the same spot, but control the process of protein degradation in a different way: Whereas ClpX does not lead to an alteration in the structure of ClpP, ADEP brings about an unintended opening of the complex. As a result, intact proteins are also degraded in an uncontrolled manner and without the support of ClpX.
The clarification of this mechanism by the research teams from Dortmund and Munich is a milestone on the way to the development of innovative antibiotic substances targeting ClpP.
The research work has been sponsored with funds from the European Research Council (ERC), the Max Planck Society and the German Research Foundation (DFG) within the scope of the Collaborative Research Center 1035 (SFB 1035) and the Cluster of Excellence Center for Integrated Protein Science Munich (CIPSM).